Sign in

Already have access? Choose your edition

Sign-in is edition-specific. New here? Start with the free brief instead of jumping straight into a trial.

Each edition has its own app, pricing, and coverage page. Use sign-in if you already have access; otherwise pick an edition and get the free daily + weekly brief first.

AI

Daily briefings on AI labs, policy, tooling, and community shifts.

Best for
  • Model releases + evals
  • Policy and safety narratives
  • Tooling and platform shifts
Featured signalUnlocked today
Anthropic has introduced Claude Design, a new AI-powered product that enables users to generate designs, prototypes, presentation slides, and marketing mater...

Crypto

Daily briefings on markets, protocols, narratives, and risk events.

Best for
  • Market structure + regulation
  • Security and exploit narratives
  • Protocol + dev ecosystem
Featured signalUnlocked today
Payward, the parent company of Kraken, has agreed to acquire Bitnomial, a U.S.-based crypto derivatives exchange fully licensed by the Commodity Futures Trad...

CYBERSECURITY

Daily briefings on vulnerabilities, incidents, and threat intel.

Best for
  • Vulns and advisories
  • Incidents + exploit narratives
  • Vendor and community disclosures
Featured signalUnlocked today
Authorities from over 20 countries collaborated in Operation PowerOFF, targeting and dismantling numerous DDoS-for-hire platforms.

ENERGY

Daily briefings on the energy transition: policy, grid, storage, and markets.

Best for
  • Grid + reliability narratives
  • Policy + first-party data
  • Storage + transition supply chain
Featured signalUnlocked today
Coverage discusses speculative scenarios around ~£600M; treat as market chatter and see linked sources.

BIOTECH

Daily briefings on clinical, regulatory, and R&D updates from public sources.

Best for
  • Clinical + regulatory narratives
  • Research + preprints
  • Funding + market updates
Featured signalUnlocked today
Recent preclinical studies introduce novel methods and mechanisms that deepen understanding of immune checkpoint inhibitor (ICI) therapy outcomes.